Wanbury reports explosive Q3 profit surge, signals strong growth ahead
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
Glucon-D maintained its leadership position with a 59% MAT market share
Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh
The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
Subscribe To Our Newsletter & Stay Updated